ArticleSmall (Weinheim an der Bergstrasse, Germany)2020
Active Delivery of VLPs Promotes Anti-Tumor Activity in a Mouse Ovarian Tumor Model.
Article in Small (Weinheim an der Bergstrasse, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 63 citations in OpenAlex.
- Suspended Microbubbles With Ultrasound Visualization and Sustained Drug Release Properties for Enhancing Intraperitoneal Perfusion Therapy.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Virus-like particles in cancer immunotherapy: bridging human and veterinary medicine through one health.Journal of nanobiotechnology · 2026Review
- Tailoring virus-inspired nanoparticles for advanced drug and gene delivery.Materials today. Bio · 2026Review
- Engineering Microbial Particles for Next-Generation Biomedical Platforms.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Engineering filamentous potato virus X as a platform nanotechnology for nucleic acid gene delivery.Scientific reports · 2025Article
- Recent advances in engineering nano/microrobots for tumor treatment.Acta pharmaceutica Sinica. B · 2025Review
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Nanomotor-enhanced transport of passive Brownian particles in porous media.Science advances · 2023Article
- Micromotor-Enabled Active Hydrogen and Tobramycin Delivery for Synergistic Sepsis Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Medical micro- and nanomotors in the body.Acta pharmaceutica Sinica. B · 2023Review
- Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer.Frontiers in pharmacology · 2023Review
- Nanomedicine Strategies for Heating "Cold" Ovarian Cancer (OC): Next Evolution in Immunotherapy of OC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Review
- Micro/Nanorobots for Medical Diagnosis and Disease Treatment.Micromachines · 2022Review
- Virus-like particles against infectious disease and cancer: guidance for the nano-architect.Current opinion in biotechnology · 2022Review
- Suitability of potyviral recombinant virus-like particles bearing a complete food allergen for immunotherapy vaccines.Frontiers in immunology · 2022Article
- "Motile-targeting" drug delivery platforms based on micro/nanorobots for tumor therapy.Frontiers in bioengineering and biotechnology · 2022Review
- Physical Disruption of Solid Tumors by Immunostimulatory Microrobots Enhances Antitumor Immunity.Advanced materials (Deerfield Beach, Fla.) · 2021Article
- Nanotechnology-Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVID-19 Vaccines.Small methods · 2021Review
- Recent progress in targeted delivery vectors based on biomimetic nanoparticles.Signal transduction and targeted therapy · 2021Review
- The pharmacology of plant virus nanoparticles.Virology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Virus-like nanoparticles (VLPs) have been used as an attractive means in cancer immunotherapy because of their unique intrinsic immunostimulatory properties. However, for treating metastatic tumors in the peritoneal cavity, such as ovarian cancer, multiple injections of therapy are needed due to the large peritoneal space and fast excretion of therapy. Here, it is reported on the development of active VLP delivery vehicles for the treatment of peritoneal ovarian tumors using biocompatible Qβ VLPs-loaded Mg-based micromotors. The autonomous propulsion of such Qβ VLPs-loaded Mg-micromotors in the peritoneal fluid enables active delivery of intact immunostimulatory Qβ VLPs to the peritoneal space of ovarian tumor bearing mice, greatly enhancing the local distribution and retention of Qβ VLPs. Such improved distribution and longer retention time of Qβ in the peritoneal cavity leads to enhanced immunostimulation and therefore increased survival rate of tumor-bearing mice compared to a passive Qβ treatment. For clinical translation, the active delivery of VLPs holds great promise for tumor immunotherapy toward the treatment of different types of primary and metastatic tumors in the peritoneal cavity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.